Suppression of acute and chronic inflammation by orally administered prostaglandins.
Oral administration of a stable analog of prostaglandin E1 (PGE1) 15-(S)-15-methyl-prostaglandin E1, can suppress both chronic adjuvant-induced polyarthritis and acute immune complex-induced vasculitis in a dose dependent manner. Histopathologic studies of tibiotarsal joints from rats with adjuvant disease showed suppression of arthritis in animals treated with the PGE1 analog from time of adjuvant challenge. This study represents the first demonstration of suppressed experimental polyarthritis by an orally administered prostaglandin. Suppression of the acute immune complex-induced vasculitis was demonstrated using 15- methyl-PGE1 administered orally 12 hours prior to antigen-antibody challenge. Diminution of tissue injury resulting from immune complex-induced vasculitis is reflected by a decrease in vaso-permeability, indicating suppressed vascular damage in animals treated with prostaglandin. These studies demonstrate the potential use of orally active prostaglandins as an antiinflammatory agent.
D000284:Administration, Oral; D000527:Alprostadil / Q000031:analogs & derivatives*; D000818:Animals; D001168:Arthritis / Q000188:drug therapy* / Q000473:pathology; D001169:Arthritis, Experimental / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D007105:Immune Complex Diseases / Q000150:complications; D007596:Joints / Q000473:pathology; D007866:Leg; D008297:Male; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew; D014657:Vasculitis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology
D011459:Prostaglandins E, Synthetic; C025170:15(S)-15-methylprostaglandin E1; D000527:Alprostadil